Moreover, subsequent studies are needed to determine whether combination therapies, such as pairing DPP-4 inhibitors with other agents like SGLT2 inhibitors (which have shown favorable outcomes in heart failure), could offset the heart failure risk. The gene discussed is SLC5A2; the disease is heart failure.